Effects of Tibolone and Continuous Combined Conjugated Equine Estrogen/Medroxyprogesterone Acetate on the Endometrium and Vaginal Bleeding: Results of the OPAL Study

American Journal of Obstetrics and Gynecology

Volumn 195, Issue 5, 2006, Pages 1320-1327

  Langer, Robert D ^a   Landgren, Britt Marie ^b   Rymer, Janice ^c   Helmond, Frans A ^d  

^a GEISINGER HEALTH SYSTEM   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CEE MPA; Endometrial safety; Hormone therapy; OPAL; Tibolone; Vaginal bleeding

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; TIBOLONE;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; BONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; TRANSVAGINAL ECHOGRAPHY; UNITED KINGDOM; UNITED STATES; UTERUS BLEEDING; VAGINA BLEEDING;

AGED; BIOPSY; CONTRACEPTIVE AGENTS, FEMALE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG TOXICITY; ENDOMETRIUM; ESTROGEN RECEPTOR MODULATORS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS; UTERINE HEMORRHAGE;

EID: 33750997318     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.03.045     Document Type: Article

References (28)

1. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. Pickar J.H., Yeh I., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76 (2001) 25-31
3. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 275 (1996) 370-375
4. Lindenfeld E.A., and Langer R.D. Bleeding patterns of the hormone replacement therapies in the postmenopausal Estrogen and Progestin Interventions Trail. Obstet Gynecol 100 (2002) 853-863
5. Kloosterboer H.J. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 48 Suppl 1 (2004) S30-S40
6. Modelska K., and Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87 (2002) 16-23
7. Gooyer de M.E., Deckers G.H., Schoonen W.G.E.J., Verheul H.A.M., and Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids 68 (2003) 21-30
8. Markiewicz L., and Gurpride E. In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 35 (1990) 535-541
9. Gooyer de M.E., Overklift Vaupel Kleyn G.T., Smits K.C., Ederveen A.G.H., Verheul H.A.M., and Kloosterboer H.J. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 183 (2001) 55-62
10. Völker W., Coelingh Bennink H.J.T., and Helmond F.A. Effects of tibolone on the endometrium. Climacteric 4 (2001) 203-208
11. Genazzani A.R., Benedek-Jaszmann L.J., Hart D.M., Andolsek L., Kicovic P.M., and Tax L. Org OD 14 and the endometrium. Maturitas 13 (1991) 243-251
12. Wender M.C., Edelweiss M.I., Campos L.S., de Castro J.A., and Spritzer P.M. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause 11 (2004) 423-429
13. Hammar M., Christau S., Nathorst-Böös J., Rud T., and Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 105 (1998) 904-911
14. Huber J., Palacios S., Berglund L., Hänggi W., Sathanandan H., Christau S., et al. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 109 (2002) 886-893
15. Dören M., Rübig A., Coelingh Bennink H.J.T., and Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 6 (1999) 299-306
16. Gallagher J.C., Baylink D.J., Freeman R., and McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of the two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 365 (2001) 4717-4726
17. Bots M.L., Evans G.W., Riley W., Meijer R., McBride K.H., Paskett E.D., et al. The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. Cont Clin Trials 24 (2003) 752-775
18. FDA. Guidance for Clinical Evaluation of Combination Estrogen/progestin-Containing Drug Products Used for Hormone Replacement Therapy of Postmenopausal Women (1995), FDA Center for Drug Evaluation and Research, Rockville (MD)
19. EMEA. Points to Consider on Hormone Replacement Therapy (1997), Human Medicines Evaluation Unit, London (UK)
20. Kurman J.R. Blaustein's Pathology of the Female Genital Tract. 4th ed. (1994), Springer-Verlag Inc., New York 411-27
21. Christodoulakos G.E., Botsis D.S., Lambrinoudaki I.V., Papagianni V.D., Panoulis C.P., Creatsa M.G., et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 53 (2006) 413-423
22. de Vries C.S., Bromley S.E., Thomas H., and Farmer R.D.T. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Safety 28 (2005) 241-249
23. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
24. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. JAMA 290 (2003) 1739-1748
25. ® study. Climacteric 7 (2004) 197-209
26. Haenggi W., Bersinger N., Altermatt H.J., and Birkhäuser M.H. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal hormone replacement therapy users. Maturitas 27 (1997) 133-143
27. Bruce D., Robinson J., and Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 7 (2004) 261-266
28. Chapman M.G. The effect of tibolone compared with CEE/MPA on bleeding rates and tolerability. Climacteric 5 Suppl 1 (2002) 214-215